Skin depigmentation results in white patches, which can occur anywhere on the body but are most commonly found on exposed areas such as the face and hands.
Conditions
Interventions
Treatment group:Ruxolitinib treatment
Sponsors
Children's Hospital,Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
2 Years to 11 Years
Inclusion criteria
Inclusion criteria: 1. Children aged 2 to 11 years, of any gender; 2. Clinically diagnosed with non-segmental vitiligo, with depigmented area (BSA) >=0.1%, T-VASI >=0.1, and total body surface area of depigmentation not exceeding 10% BSA; 3. The patient’s legal guardian voluntarily signs the informed consent form and agrees to regular follow-up.
Exclusion criteria
Exclusion criteria: 1. Diagnosis of other forms of vitiligo (e.g., segmental vitiligo); 2. Presence of other skin depigmentation disorders that may affect the evaluation of efficacy (e.g., pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macular hypomelanosis, nevus anemicus, tinea versicolor, etc.); 3. Previous or current use of depigmenting treatments; 4. History of failure of any systemic or topical JAK inhibitor treatment for vitiligo or any other inflammatory disease; 5. Allergy to the investigational drug or its excipients; 6. Participation in another clinical study; 7. Judged by the investigator as unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Vitiligo Area Scoring Index, T-VASI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Family Dermatology Life Quality Index, FDLQI;Children's Dermatology Life Quality Index, CDLQI;Vitiligo Noticeability Scale, VNS;Pediatric Quality of Life Inventory, PedsQL; | — |
Countries
China
Contacts
Public ContactRen Yunqing
Children's Hospital,Zhejiang University School of Medicine
Outcome results
None listed